462 results on '"Shah, Mithun V"'
Search Results
52. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients
53. Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
54. Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy
55. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
56. Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
57. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
58. Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
59. Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
60. High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group
61. Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
62. Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
63. IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
64. Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
65. Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
66. Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
67. Efficacy of MEK Inhibitors in Erdheim Chester Disease
68. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
69. Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms
70. Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
71. Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
72. BRAFV600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
73. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
74. Somatic TP53single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)
75. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease
76. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease
77. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.
78. Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies
79. Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms
80. Clinical Outcomes of Pretransplant Mortality Prediction Models in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplant
81. Elevated Pre-Transplant Ferritin Is Associated with Development of Liver Graft-Vs-Host Disease in Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation
82. MULTI-MODALITY CARDIAC IMAGING OF ERDHEIM-CHESTER DISEASE
83. Metformin and Cytokine Release Syndrome after Immune Effector Cell Therapy
84. Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience
85. Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience
86. Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies
87. Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia
88. Tumor Mutational Burden in Histiocytic Neoplasms
89. Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN)
90. Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience
91. Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia
92. Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups
93. Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy
94. Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy
95. Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings
96. Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy
97. Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90
98. BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics
99. T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML
100. Efficacy of Cobimetinib in Rosai-Dorfman Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.